VivoSeq
Oncology

Endometrial Cancer

238

Pipeline Programs↗

113

Active Trials↗

90

Companies Involved↗

Endometrial Cancer is a highly competitive landscape with 238 programs across 90 companies. The most active players are Sutro Biopharma, Inc., Biogenea Pharmaceuticals Ltd., Ferring. 8 therapies are approved with 42 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

85/100

Pipeline Velocity

57/100

Mech. Concentration

5/100

Completion Rate

74/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sutro Biopharma, Inc.

1 program

Phase 1B

Biogenea Pharmaceuticals Ltd.

1 program

Phase 1Ferring logo

Ferring

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1S

Syndax Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical13

Indocyanine Green

CHX Technologies Inc.

Dostarlimab

Glaxo Dba Glaxosmithkline

Semaglutide

Novo Nordisk

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Zolpidem

Purdue Pharma LP

Phase 130

Aromatase Inhibitor

Pfizer

Alpelisib

Novartis

Progesterone

Ferring

Tislelizumab

BeiGene

Lapatinib

GSK

Phase 2145

Trastuzumab

Organon and Co

Pemetrexed Disodium

Gynecologic Oncology Group

Tirzepatide

Eli Lilly

Lapatinib Ditosylate

Novartis

Crizotinib

Prism Pharmaceuticals

Phase 342

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Docetaxel

Avyxa

Carboplatin

Avyxa

Paclitaxel

Teva

Selinexor

Karyopharm Therapeutics Inc

Approved8

Exemestane

Pfizer

Celecoxib

Philadelphia Eye Associates

Lurbinectedin

Jazz Pharmaceuticals

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Low-Dose Aspirin

PharmaEssentia Japan K.K.

Analysis

Modality Breakdown

82%

Small molecule

207 of 252 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody2711%Protein / enzyme62%Antibody–drug conjugate42%Peptide31%Vaccine2<1%Radiopharmaceutical2<1%Other1<1%

Small molecule leads; the ring shows all 252 classified programs, each share of the total. Modality classified for 100% of 259 pipeline programs.

Analysis

Trial Status

309

clinical trials

Completed120 · 39%
Recruiting52 · 17%
Active, not recruiting35 · 11%
Unknown status34 · 11%
Terminated29 · 9%
Not yet recruiting25 · 8%
Other14 · 5%

Clinical Trials

Trial Activity

309 trials

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT07022483·710 enrolled
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT06712472·554 enrolled
SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
Recruiting·QQueensland Centre for Gynaecological Cancer·Phase 2·NCT06278857·10 enrolled
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Recruiting·—·Phase 2/3·NCT06379113·29 enrolled
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Recruiting·—·Phase 1·NCT07278986·10 enrolled
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Recruiting·GSK logoGSK·Phase 2·NCT07108270·30 enrolled
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07209449·75 enrolled
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Recruiting·YYonsei University·Phase 2·NCT06502743·92 enrolled
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Recruiting·RRadboud University Medical Center·N/A·NCT03621904·150 enrolled
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT07054567·96 enrolled
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Recruiting·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2·NCT06561308·39 enrolled
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Recruiting·—·Phase 2·NCT06413992·117 enrolled
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06917092·30 enrolled
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Recruiting·YYonsei University·Phase 2·NCT05795244·30 enrolled
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Recruiting·AAadi Bioscience, Inc.·Phase 2·NCT05997017·29 enrolled
Page 1 of 21

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)